cohort. The authors call for the development of predictive biomarkers and novel drug combinations to further enhance outcomes.In conclusion, the contributions to this Special Topic section underscore the dynamic and multifaceted nature of resistance to tumour angiogenesis therapies. By identifying new molecular targets, validating innovative combination therapies, and emphasising the significance of patient stratification, these studies provide guidance for developing more effective and sustainable antiangiogenic strategies. Overcoming resistance will require continued collaboration across disciplines, integration of emerging scientific insights, and a steadfast commitment to patient-centred care.
Mabeta et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: